Non-Hodgkin Lymphoma Market Growth, Trends & Forecast 2025 | Top key players - AbbVie, Inc., AstraZeneca plc, Bayer AG.

The Global Non-Hodgkin Lymphoma Market reached USD 7.3 billion in 2023 and is projected to witness lucrative growth by reaching up to USD 13.5 billion by 2031. The global non-Hodgkin lymphoma market is expected to exhibit a CAGR of 8.2% during the forecast period 2024-2031.

The Non-Hodgkin Lymphoma Market, as examined in the DataM Intelligence study, offers a comprehensive overview of the industry, enriched with in-depth insights, historical data, and key statistics. The report provides a thorough analysis of market dynamics, competitive strategies, and leading players, detailing their product offerings, pricing models, financial performance, expansion strategies, and regional presence.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID) @ https://datamintelligence.com/download-sample/non-hodgkin-lymphoma-market?sz

The Clinical Diagnostics Market refers to the industry involved in the development, production, and sale of medical tests and tools used to detect, diagnose, and monitor diseases. It encompasses laboratory tests, point-of-care testing, and molecular diagnostics. These diagnostics support clinical decision-making, enabling early disease detection, effective treatment planning, and improved patient outcomes across various healthcare settings.

Key Development

On December 22, 2022, Genentech, part of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for Lunsumio® (mosunetuzumab-axgb). This new treatment is for adult patients with relapsed or refractory follicular lymphoma (FL) who have undergone at least two prior systemic therapies. Lunsumio is a fixed-duration cancer immunotherapy that works as a CD20xCD3 T-cell-engaging bispecific antibody, and because it's an off-the-shelf product, patients can start treatment without delay. While the approval is based on response rates, further studies are needed to confirm its long-term benefits.

On January 27, 2023, Loxo Oncology, the oncology division of Eli Lilly and Company, announced FDA approval for Jaypirca® (pirtobrutinib) tablets (available in 100 mg and 50 mg doses). Jaypirca is approved for adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have already received at least two lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor.

Major Players Shaping the Non-Hodgkin Lymphoma Market:

The prominent players in Non-Hodgkin Lymphoma market research report are: AbbVie, Inc. (Pharmacyclics LLC), AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company (Celgene Corp.), Gilead Sciences, Inc. (Kite Pharma), Johnson & Johnson (Janssen Biotech, Inc.), Merck & Co., Inc., Novartis AG, Roche Holding AG (F. Hoffmann-La Roche AG), Seagen, Inc. (Seattle Genetics, Inc.), Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd. among others.

The companies are primarily focusing on strategies such as new product launches to penetrate the fastest-growing emerging markets across the world.

Speak to Our Senior Analyst and Get Customization in the report as per your requirements @ https://datamintelligence.com/customize/non-hodgkin-lymphoma-market

Market Segments

By Disease Type: B-cell Lymphomas, T-cell Lymphoma.

By Drug Class: Monoclonal Antibodies, Antibody-Drug Conjugates, BTK/BCL-2 Kinase Inhibitors, PI3 Kinase Inhibitors, Protease Inhibitors, PD1 Inhibitors, Immunomodulatory Drugs, Chemotherapy Agents, CAR T-Cell Therapy.

By Route of Administration: Oral, Parenteral, Others.

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

The Non-Hodgkin Lymphoma industry is experiencing rapid growth, driven by advancements in medical technologies, increased demand for innovative therapies, and a rising focus on patient-centered care. As these sectors evolve, the need for comprehensive market analysis becomes crucial to understand trends, regulatory changes, and emerging opportunities.

Regions Covered:

The global Non-Hodgkin Lymphoma Market report focuses on six major regions: North America, South America, Europe, Asia Pacific, the Middle East, and Africa.

☞ North America - US, Canada, Mexico

☞ Europe- Germany, Russia, UK, France, Italy, Rest of Europe

☞ Asia Pacific- China, India, Japan, Australia, Rest of Asia Pacific

☞ South America- Brazil, Argentina, Colombia, Rest of South America

☞ Middle East and Africa- Saudi Arabia, UAE, Oman, Bahrain, Qatar, Kuwait, Israel

Benefits of the Report:

➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.

➡ Top-down and bottom-up approach for regional analysis

➡ Porter's five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players.

➡ By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Market

Stay informed with the latest industry insights-start your subscription now: https://www.datamintelligence.com/reports-subscription

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.